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Live/Dead staining analysis Briefly, hydrogels (20 µL) were synthesized using a bacterial concentration 50 times higher than the in vivo studies to achieve a concentration high enough for practical microscopic analysis. Hydrogels synthesized with and without lysostaphin were incubated in PBS at room temperature for 4 hours to simulate conditions prior to implantation. Afterwards, live/dead staining was performed using BacLight Bacterial Viability Kit L7007 (Life Technologies Corporation), in which 1 µL of Component A/Component B mixture was added to the gel and incubated for 15 minutes before analysis. Confocal microscopy was performed using a Nikon C2 Eclipse Ti inverted microscope using a 10X objective and a 488 nm laser. SYTO 9 fluorescence was detected using a 525/50 nm filter cube and propidium iodide was detected using a 595/50 nm filter cube. Images were analyzed using Fiji software. Cell counting was performed on each individual filter for all conditions, in which percent live bacteria was determined by the number of counts on the live filter divided by the total counts. Kruskal-Wallis test with Dunn's multiple comparaisons test. Means ± SD. N=5-11 per group. *** P < 0.001; **** P < 0.0001. Fig. S4 . Lysostaphin-delivering hydrogels eliminate infection at 8 weeks. Viable bacteria recovered from UAMS-1 infected radial defects 8 weeks post-implantation. Kruskal-Wallis test with Dunn's multiple comparisons test. Means ± SD. N=7-8 per group. *** P < 0.001. Fig. S5 . BMP-2-loaded lysostaphin-delivering hydrogels do not show signs of systemic toxicity. Segmental defects were created and lysostaphin-delivering hydrogels loaded were BMP-2 with and without infection were implanted. Systemic toxicity was assessed at 1 week with liver function testing. Serum samples were tested for total protein (A), albumin (B), aspartate aminotransferase (AST) (C), alanine aminotransferase (ALT) (D), and alkaline phosphatase (Alk phosphatase) (E) levels. Means ± SD. N=5-6 per group. One-way ANOVA with Tukey's post-hoc test. No differences were detected between groups. Hi IM monocytes as a percent of CD11b+ cells were analyzed. Ordinary one-way ANOVA with a Tukey post hoc test, or Kurskall-Wallis with Dunn's test for non-parametric data was used. Means ± SD. N=7 per group. *P<0.05, ***P < 0.001, ****P < 0.0001.
